Roche AG (RHHBY) remains fully committed to its mooted acquisition of the 44% of Genentech Inc. (DNA) that it doesn't already own, the company's chief financial officer, Erich Hunziker, said Monday.

Speaking at the J.P. Morgan Healthcare conference in San Francisco, Hunziker said Roche wouldn't damage the research and development departments at the California-based company if the transaction was successful.

- By Jessica Hodgson, Dow Jones Newswires; 415-439-6455; jessica.hodgson@dowjones.com

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary. You can use this link on the day this article is published and the following day.